Cholesteryl Ester Transfer Protein and Its Inhibitors

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2018 Mar 1

PMID 29487091

Citations 33

Authors

Sudichhya Shrestha

Ben J Wu

Liam Guiney

Philip J Barter

Kerry-Anne Rye

Affiliations

Soon will be listed here.

Abstract

Most of the cholesterol in plasma is in an esterified form that is generated in potentially cardioprotective HDLs. Cholesteryl ester transfer protein (CETP) mediates bidirectional transfers of cholesteryl esters (CEs) and triglycerides (TGs) between plasma lipoproteins. Because CE originates in HDLs and TG enters the plasma as a component of VLDLs, activity of CETP results in a net mass transfer of CE from HDLs to VLDLs and LDLs, and of TG from VLDLs to LDLs and HDLs. As inhibition of CETP activity increases the concentration of HDL-cholesterol and decreases the concentration of VLDL- and LDL-cholesterol, it has the potential to reduce atherosclerotic CVD. This has led to the development of anti-CETP neutralizing monoclonal antibodies, vaccines, and antisense oligonucleotides. Small molecule inhibitors of CETP have also been developed and four of them have been studied in large scale cardiovascular clinical outcome trials. This review describes the structure of CETP and its mechanism of action. Details of its regulation and nonlipid transporting functions are discussed, and the results of the large scale clinical outcome trials of small molecule CETP inhibitors are summarized.

Citing Articles

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Bril F, Berg G, Barchuk M, Nogueira J J Lipid Atheroscler. 2025; 14(1):5-29.

PMID: 39911965 PMC: 11791423. DOI: 10.12997/jla.2025.14.1.5.

Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention.

Hu W, Feng H, Liu Y, Xu X, Zhou P, Sun Z Hum Vaccin Immunother. 2025; 21(1):2462466.

PMID: 39907207 PMC: 11801355. DOI: 10.1080/21645515.2025.2462466.

Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?.

Tsioulos G, Vallianou N, Skourtis A, Dalamaga M, Kotsi E, Kargioti S Biomolecules. 2025; 14(12.

PMID: 39766344 PMC: 11727084. DOI: 10.3390/biom14121637.

Cognitive impairment and depression precede increased HDL-C levels in middle-aged and older Chinese adults: cross-lagged panel analyses.

Liu Y, Chen M, He Y, Chen M, Liang J, Jia F Lipids Health Dis. 2024; 23(1):288.

PMID: 39252009 PMC: 11382475. DOI: 10.1186/s12944-024-02285-9.

Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions.

Li X, Li M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204178 PMC: 11358954. DOI: 10.3390/ph17081073.

References

Seip R, Moulin P, Cocke T, Tall A, Kohrt W, Mankowitz K . Exercise training decreases plasma cholesteryl ester transfer protein. Arterioscler Thromb. 1993; 13(9):1359-67. DOI: 10.1161/01.atv.13.9.1359. View

Ridker P, Pare G, Parker A, Zee R, Miletich J, Chasman D . Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2009; 2(1):26-33. PMC: 2729193. DOI: 10.1161/CIRCGENETICS.108.817304. View

Lauer M, Graff-Meyer A, Rufer A, Maugeais C, von der Mark E, Matile H . Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP. J Struct Biol. 2016; 194(2):191-8. DOI: 10.1016/j.jsb.2016.02.016. View

Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S . Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39(2):165-228. PMC: 7095153. DOI: 10.1007/s00134-012-2769-8. View

Foger B, Chase M, Amar M, Vaisman B, Shamburek R, Paigen B . Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem. 1999; 274(52):36912-20. DOI: 10.1074/jbc.274.52.36912. View

Hannuksela M, Liinamaa M, Kesaniemi Y, Savolainen M . Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis. 1994; 110(1):35-44. DOI: 10.1016/0021-9150(94)90065-5. View

Niu W, Qi Y . Circulating cholesteryl ester transfer protein and coronary heart disease: mendelian randomization meta-analysis. Circ Cardiovasc Genet. 2015; 8(1):114-21. DOI: 10.1161/CIRCGENETICS.114.000748. View

Zhang L, Yan F, Zhang S, Lei D, Charles M, Cavigiolio G . Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol. 2012; 8(4):342-9. PMC: 3792710. DOI: 10.1038/nchembio.796. View

Stenkula K, Lindahl M, Petrlova J, Dalla-Riva J, Goransson O, Cushman S . Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice. Diabetologia. 2014; 57(4):797-800. PMC: 3940850. DOI: 10.1007/s00125-014-3162-7. View

10.

Cazita P, Barbeiro D, Moretti A, Quintao E, Soriano F . Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock. 2008; 30(5):590-5. DOI: 10.1097/SHK.0b013e31816e30fd. View

11.

Gautier T, de Haan W, Grober J, Ye D, Bahr M, Claudel T . Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. J Lipid Res. 2013; 54(8):2195-2205. PMC: 3708369. DOI: 10.1194/jlr.M038141. View

12.

Gotto Jr A, Cannon C, Li X, Vaidya S, Kher U, Brinton E . Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2013; 113(1):76-83. DOI: 10.1016/j.amjcard.2013.08.041. View

13.

Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H . A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000; 406(6792):203-7. DOI: 10.1038/35018119. View

14.

Bocan T, Mueller S, Mazur M, Uhlendorf P, Brown E, Kieft K . The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation. Atherosclerosis. 1993; 102(1):9-22. DOI: 10.1016/0021-9150(93)90080-e. View

15.

Castro-Perez J, Briand F, Gagen K, Wang S, Chen Y, McLaren D . Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res. 2011; 52(11):1965-73. PMC: 3196228. DOI: 10.1194/jlr.M016410. View

16.

Inazu A, Jiang X, Haraki T, Yagi K, Kamon N, Koizumi J . Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest. 1994; 94(5):1872-82. PMC: 305391. DOI: 10.1172/JCI117537. View

17.

Barter P, Rye K, Tardif J, Waters D, Boekholdt S, Breazna A . Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011; 124(5):555-62. DOI: 10.1161/CIRCULATIONAHA.111.018259. View

18.

Rocco D, Okuda L, Pinto R, Ferreira F, Kubo S, Nakandakare E . Aerobic exercise improves reverse cholesterol transport in cholesteryl ester transfer protein transgenic mice. Lipids. 2011; 46(7):617-25. DOI: 10.1007/s11745-011-3555-z. View

19.

Swenson T, Hesler C, Brown M, Quinet E, Trotta P, Haslanger M . Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope. J Biol Chem. 1989; 264(24):14318-26. View

20.

Cai L, Ji A, de Beer F, Tannock L, van der Westhuyzen D . SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest. 2007; 118(1):364-75. PMC: 2117761. DOI: 10.1172/JCI31539. View